ImetelChat

would imagine that make Geron more attractive for acquisition

maybe it was extended to keep it out of he ADCOM discussion - the impress patients are near life's end and they dont want to complicate their approval for MDS

I think as time goes on raising the hemoglobin 1.5 g with command and not changing how the patient feels will have people reassessing. I think people are going to start to want to modify the disease and they’re going to want to feel better also.

Today is also a day of interest - 1/30/24

https://www.youtube.com/watch?v=8Mnyrt7bAQQ

what a strong endorsement for AML for a treated patient - i am looking forward to seeing that data

how many of these shares are newly purchased

the job posting " for huge potential for patients across hematology disease states"
interesting phrasing

and of course the question is - how can that be the answer for a drug that is not approved

i think as imetelstat is used and practitioners become comfortable and see the significant HgB increase its market share will keep increasing

there was the post the other day about the guy on imtetelstat and feeling better than he had in the last 5 years ( I was also suspicious of his start day on Jan 23) - and it reminded me of the lady in australia that was on the news who received imetelstat for AML from Dr Lane and said how great she ...

i did not register and reply to it - I thought it might be inappropriate considering my position - I have a feeling that story will be a common one

I think we all can read this and think what would probably be helpful and it is shameful it was not approved on a priority basis - "My mother’s is diagnosed for Myelodysplastic syndrome (MDS) and Erythropoietin was the treatment. In the beginning, Erythropoietin seems to work for my mother but now w...

my guess - after these people are hired and given their options we will see the stock price rise

one step closer to revenue

my mistake - have gotten used to disappointment - would be nice if we could get approved a couple months early

says PDUFA June 16th and review completion by end of 2024?

https://www.youtube.com/watch?v=owIlqs_a-6A

around 47 minute mark and listen to the questions at the end - think there is a lot of interest in imetelstat due to treating high transfusion burden and also the ability to modify the disease

a very good listen - a nice long discussion on imetelstat - still surprised did not get priority review